Organization | Gracell Biotechnology Ltd.

Gracell Biotechnology Ltd. Report issue

For profit Phase 1 Phase 2

Founded: Suzhou China (2017)

Organization Overview

First Clinical Trial

2018

NCT03559439

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Gracell Biotechnologies (Shanghai) Co., Ltd | Gracell Biotechnology Ltd. | Gracell Biotechnology Shanghai Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

gc012f (4 trials)

gc022 (4 trials)

Drugs in Phase 1 Trials (10)

anti-cd19 fast car-t cells (1 trial)

bcma/cd19 dual-target car-t (2 trials)

cd19 allo-car-t cells (1 trial)

cd19 car-t cells (5 trials)

cd22 car-t cells (1 trial)

cd7 car-t cell (1 trial)

cyclophosphamide (cytoxan) (2 trials)

fludarabine (fludara) (2 trials)

gc007f (1 trial)

melphalan (alkeran) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hematologic Neoplasms (Phase 2)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, T-Cell (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 19
# of Trial APIs: 12